Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Epithelial Carcinoma | Preclinical | US | 21 Jul 2024 |